Meeting
2020 ASCO Virtual Scientific Program
SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
Authors
Dejka M. Araujo
The University of Texas MD Anderson Cancer Center, Houston, TX
Dejka M. Araujo , Mihaela Druta , Mark Agulnik , Sandra P. D'Angelo , Jean-Yves Blay , Sandra J Strauss , Claudia Valverde , Albiruni Ryan Abdul Razak , Erin Van Winkle , Trupti Trivedi , Swethajit Biswas , Dennis Williams , Elliot Norry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04044768
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS11569)
DOI
10.1200/JCO.2020.38.15_suppl.TPS11569
Abstract #
TPS11569
Poster Bd #
457
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.
First Author: Sandra P. D'Angelo
Poster
2017 ASCO Annual Meeting
A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).
First Author: Sandra P. D'Angelo
Poster
2022 ASCO Annual Meeting
![Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.](https://d201v5jt9ylckg.cloudfront.net/288/14409/210696/210696_A3144_poster_pv.jpg)
Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.
First Author: Sandra P. D'Angelo
Poster
2022 ASCO Annual Meeting
![ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].](https://d201v5jt9ylckg.cloudfront.net/288/14355/213211/213211_A1227_poster_pv.jpg)
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].
First Author: Dejka M. Araujo